| Over a week ago | ||||
BTIG analyst Dae Gon Ha… BTIG analyst Dae Gon Ha initiated coverage of Amicus with a Buy rating and $19 price target. The company's oral precision medicine Galafold continues to generate revenue growth worldwide across both enzyme replacement therapy-switchers and treatment-naive patients, the analyst tells investors in a research note, adding that the drug's success de-risks the company's proprietary chaperone advanced replacement therapy technology. | ||||
Conference call with… Conference call with management will be held on June 16 at 1 pm hosted by Cantor Fitzgerald. | ||||
After Sanofi (SNY)… After Sanofi (SNY) reported data from its Phase 3 COMET study, which evaluated avalglucosidase alfa, or "NeoGAA," in enzyme replacement therapy naive late-onset Pompe disease patients, H.C. Wainwright analyst Debjit Chattopadhyay said the "overall picture emerging from" the COMET program has positive implications for the Amicus-sponsored PROPEL Phase 3 program. The analyst, who expects Amicus' AT-GAA to perform better than NeoGAA in switch patients, reiterates his Buy rating and $20 price target on Amicus (FOLD) shares. | ||||
Conference call with… Conference call with management will be held on June 16 at 1 pm hosted by Cantor Fitzgerald. | ||||
Conference call with… Conference call with management will be held on June 16 at 1 pm hosted by Cantor Fitzgerald. | ||||
Citi analyst Mohit Bansal… Citi analyst Mohit Bansal attributes the weakness yesterday in shares of Amicus Therapeutics (FOLD) to Sanofi's (SNY) press release indicating that the company will release Phase 3 data for avalglucosidase alfa at a virtual science session on June 16. This is a key event for Amicus as this neoGAA would compete with its investigational drug AT-GAA, Bansal tells investors in a research note. Given the company issued a press release about hosting such an event, investors are likely putting a high probability to neoGAA's success, hence the weakness in Amicus shares, says the analyst. However, he sees enough differences between the respective Phase 3 programs that it is not easy to compare neoGAA data with AT-GAA on an apples to apples basis. Further, Amicus does not get much credit for AT-GAA in current valuation as fair value of the company is $10 per share on Galafold alone, contends Bansal. The analyst keeps a Buy rating on the shares with a $15 price target. | |
JPMorgan analyst Anupam… JPMorgan analyst Anupam Rama noted that shares of Amicus (FOLD) were under pressure today following the Sanofi (SNY) neoGAA Pompe update. The analyst believes the weakness in Amicus shares is "overdone," saying "we have known for some time that the neoGAA COMET data would be a Q2 event." Rama said that Amicus "continues to be a top idea... driven by commercial Galafold, AT-GAA Pompe program, and gene therapy optionality." The analyst reiterated an Overweight rating on Amicus shares. |
| Over a month ago | ||||
JPMorgan analyst Anupam… JPMorgan analyst Anupam Rama raised the firm's price target on Amicus to $21 from $18 and keeps an Overweight rating on the shares. | ||||
Janney Montgomery Scott… Janney Montgomery Scott analyst Yun Zhong reiterates Buy rating and $20 fair value estimate on Amicus shares following the company's Q1 update, which suggested only modest impacts on both Galafold's launch and the ongoing clinical programs due to COVID-19. Management reiterated its guidance on 2020 revenue and a top-line Pompe data readout in the first half of 2021, noted Zhong, who sees Amicus having a portfolio of assets at different stages from preclincal to commercial and strong long-term potential from its gene therapy pipeline. | ||||
Amicus Therapeutics… Amicus Therapeutics announced that its 2020 Annual Meeting of Stockholders will now be held solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health and well-being of our employees, stockholders and directors. As previously announced, the 2020 Annual Meeting will be held on June 4, 2020 at 9:00 am ET. | ||||